Regeneron Q3 sales sans COVID products grow on back of blockbuster Eylea

Nov. 03, 2022 7:12 AM ETRegeneron Pharmaceuticals, Inc. (REGN), SNYBy: Ravikash, SA News Editor

Digital Eye Wave Lines Stock Background

Sharamand/iStock via Getty Images

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 revenues excluding COVID-19 therapies grew as blockbusters Eylea and Dupixent drove up sales.

Q3 non-GAAP EPS declined -28% Y/Y to $11.14, while total revenue fell -15% Y/Y to $2.94B.

Total revenues excluding

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.